CN112472719A - A powder containing linarin as main ingredient for preventing and treating fatty liver of perinatal milk cow - Google Patents
A powder containing linarin as main ingredient for preventing and treating fatty liver of perinatal milk cow Download PDFInfo
- Publication number
- CN112472719A CN112472719A CN202011285132.5A CN202011285132A CN112472719A CN 112472719 A CN112472719 A CN 112472719A CN 202011285132 A CN202011285132 A CN 202011285132A CN 112472719 A CN112472719 A CN 112472719A
- Authority
- CN
- China
- Prior art keywords
- linarin
- parts
- liver
- fatty liver
- rumen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
Abstract
A powder preparation using linarin as a main component for preventing and treating fatty liver of dairy cows in perinatal period belongs to the technical field of livestock drug. The invention aims to provide a powder which is prepared from main active ingredients of linarin in wild chrysanthemum, soybean lecithin capable of increasing the solubility of linarin, rumen-bypass glucose and the like, is prepared into a special formula and takes linarin as a main ingredient to prevent and treat fatty liver of dairy cows in a perinatal period. The effective components of the invention are: rumen-protected glucose, calcium bicarbonate, rumen-protected choline, iodized salt, sodium bicarbonate, sodium selenite, soybean phospholipid, and linarin. The invention can obviously improve the liver fat accumulation and the energy negative balance of the fatty liver dairy cows in the perinatal period.
Description
Technical Field
The invention belongs to the technical field of livestock drugs.
Background
Perinatal period is the most challenging period in the process of raising dairy cows, during which the normal physiological processes and metabolic functions of dairy cows are drastically changed. On the one hand, the body's energy demand is greatly increased due to pregnancy, parturition and lactation, and on the other hand, the dry matter intake of cows is reduced, resulting in a state of negative energy balance. In order to compensate for energy deficiency, the body mobilizes fat to supply energy, a large amount of non-esterified fatty acids (NEFA) are generated to enter blood and are absorbed by the liver in a large amount, part of the NEFA generates ATP, carbon dioxide and water through complete oxidation, a large amount of NEFA can be re-esterified into triglyceride to be accumulated in the liver to cause liver lipid accumulation, meanwhile, lipotoxicity of the NEFA can damage the homeostasis of liver cells to aggravate the liver lipid accumulation and liver injury, and the occurrence and development of fatty liver are caused.
Excessive liver fat accumulation reduces the lactation performance of the dairy cows, causes the cows to have poor appetite, and increases the risk of mastitis and endometritis. In addition, accumulation of liver fat causes insulin resistance, promotes de novo synthesis of liver fat, and further exacerbates the development of fatty liver. Therefore, the prevention of liver lipid accumulation is an effective way for preventing and treating glycolipid metabolic disorder diseases such as fatty liver of perinatal dairy cows.
In the field of dairy cow breeding, medicaments or feed additives for improving the immunity of dairy cows in a perinatal period or preventing and treating various infectious diseases are reported, but the feed additives for preventing or treating liver fat accumulation of the dairy cows in the perinatal period are quite lacking.
Disclosure of Invention
The invention aims to provide a powder which is prepared from main active ingredients of linarin in wild chrysanthemum, soybean lecithin capable of increasing the solubility of linarin, rumen-bypass glucose and the like, is prepared into a special formula and takes linarin as a main ingredient to prevent and treat fatty liver of dairy cows in a perinatal period.
The invention comprises the following active ingredients in parts by weight: 29-33 parts of rumen bypass glucose, 15-20 parts of calcium bicarbonate, 10-15 parts of rumen bypass choline, 6-10 parts of iodized salt, 10-14 parts of baking soda, 6-11 parts of sodium selenite, 4-8 parts of soybean phospholipid and 2-4 parts of linarin.
The invention can obviously improve the liver fat accumulation and the energy negative balance of the fatty liver dairy cows in the perinatal period. The method has the following beneficial effects:
1. the main component of the powder for preventing and treating the fatty liver of the perinatal dairy cows is linarin, and the powder can reduce the content of malondialdehyde, total cholesterol and triglyceride in serum of fatty liver mice, promote the oxidative decomposition of lipid in the liver and the output of triglyceride, reduce the deposition of the triglyceride in the liver and has no toxic or side effect. In addition, the linarin can promote the transfer of the Transcription Factor EB (TFEB) from cytoplasm to nucleus, further regulate and control the downstream autophagy and the expression of genes related to lysosomes, improve the autophagy and lysosome functions of cells, accelerate the metabolic level of the cells, facilitate the removal of excessive lipid by liver cells, and further relieve the accumulation of liver lipid. The research finds that the linarin can relieve acute liver injury induced by LPS by inhibiting oxidative stress and inflammation, which shows that the linarin has an obvious liver protection effect and is possibly helpful for relieving the toxic effect of high-concentration NEFA on liver cells. Meanwhile, the linarin has the defects of low solubility and low bioavailability in biological absorption as the main active ingredient of the wild chrysanthemum flower, so that the soybean phospholipid is added into the powder and combined with the linarin to form an linarin phospholipid complex, so that the solubility and the bioavailability of the linarin can be remarkably improved, and the soybean phospholipid serving as a soybean extract with an obvious liver protection effect can relieve the toxic effect of high-concentration NEFA on liver cells.
2. The rumen-bypass glucose, calcium bicarbonate, rumen-bypass choline and mineral elements are added into the powder for preventing and treating fatty liver of the perinatal dairy cows, so that the postpartum dairy cows can quickly recover energy supply, and energy negative balance and mineral deficiency caused by insufficient dry matter intake of the perinatal dairy cows are effectively prevented. In addition, researches show that the rumen bypass choline and selenium supplement can play a more obvious dual protection role on the liver, the choline can promote the synthesis of Very Low Density Lipoprotein (VLDL) of the liver cells and reduce the accumulation of triglyceride of the liver cells, the selenium has obvious antioxidant capacity and weakens the oxidative damage effect of high NEFA on the liver cells, and the choline and the VLDL can mutually promote in the liver, so that the benign circulation is realized, and the metabolic pressure of the liver is effectively relieved. Therefore, the invention has the advantages of preventing and treating the hepatic lipopexia of the perinatal fatty liver dairy cows, relieving the deficiency of energy and mineral substances of the perinatal dairy cows, reducing the risks of the perinatal dairy cows suffering from other diseases such as ketosis and the like, and further reducing the breeding cost of the dairy cows. The product is optimized through a large number of experiments, and has high safety and obvious effect.
3. The powder for preventing and treating the fatty liver of the perinatal dairy cows has the advantages of easily available raw materials, low price, good taste, simple, safe and effective use, and clinical tests prove that the powder can effectively reduce the liver fat accumulation of the perinatal dairy cows, reduce the breeding cost and increase the income of breeding enterprises.
Detailed Description
The invention comprises the following active ingredients in parts by weight: 29-33 parts of rumen bypass glucose, 15-20 parts of calcium bicarbonate, 10-15 parts of rumen bypass choline, 6-10 parts of iodized salt, 10-14 parts of baking soda, 6-11 parts of sodium selenite, 4-8 parts of soybean phospholipid and 2-4 parts of linarin.
The components are ground into powder and then mixed to obtain the powder of the invention.
Example 1
The invention comprises the following active ingredients in parts by weight: rumen bypass glucose 29, calcium bicarbonate 15, rumen bypass choline 10, iodized salt 6, baking soda 10, sodium selenite 6, soybean lecithin 4, and linarin 2.
The preparation method is the same as above.
Example 2
The invention comprises the following active ingredients in parts by weight: 30 parts of rumen-protected glucose, 18 parts of calcium bicarbonate, 11 parts of rumen-protected choline, 9 parts of iodized salt, 12 parts of baking soda, 10 parts of sodium selenite, 8 parts of soybean lecithin and 4 parts of linarin.
The preparation method is the same as above.
Example 3
The invention comprises the following active ingredients in parts by weight: rumen-protected glucose 31, calcium bicarbonate 17, rumen-protected choline 12, iodized salt 8, baking soda 12, sodium selenite 8, soybean lecithin 6 and linarin 3.
The preparation method is the same as above.
Example 4
The invention comprises the following active ingredients in parts by weight: 33 parts of rumen-protected glucose, 20 parts of calcium bicarbonate, 15 parts of rumen-protected choline, 10 parts of iodized salt, 14 parts of baking soda, 11 parts of sodium selenite, 8 parts of soybean lecithin and 4 parts of linarin.
The preparation method is the same as above.
Test example: the experiment mainly embodies the effects of the powder in two aspects of prevention and treatment, and provides the following operation steps:
s1, for the prevention experiment group, 80 healthy cows with similar gestational age, body condition and expected delivery period in an intensive cow farm are selected and divided into 40 control groups and 40 treatment groups. For the treatment experiment, 40 cows with similar gestational age, age and body condition and fatty liver (the wet weight of triglyceride in liver is more than 1%) in an intensive cow farm are selected and divided into 20 cows in a fatty liver group and a treatment group;
s2, feeding the cows of the prevention and treatment experimental group according to NRC standard, and irrigating the cows on the 6 th day before delivery and the 3 rd day before delivery respectively for the prevention experiment. For the treatment experiments, the administration was performed once on the day of confirmation of fatty liver, on day 3, day 6 and day 9, respectively. When the product is taken in a bag, the product is taken out and added into 5L of water with the temperature of 37 ℃ before eating, the mixture is taken in a bag after being mixed, and other feeding processes are normal.
S3, experimental operation: the control group and the fatty liver group in the prevention and treatment experimental group do not take powder, only water with the same dosage is drenched, the control group and the fatty liver group are raised according to the normal flow of a farm, and the treatment group are added into the water according to the optimized powder ratio and drenched.
In addition, since the product is administered before eating, the stomach catheter is easily inserted into the lung during administration, which causes abnormal lung injury, and therefore, a certain amount of knowledge of the veterinarian is required for administration.
In order to coordinate the above experiments, the following experimental data are now provided:
the prevention and treatment experimental group is fed equally according to NRC standard, and for the prevention experimental group, blood and liver tissues are collected on the 10 th day after delivery for detecting blood metabolism indexes and indexes related to liver fat metabolism; for a treatment experiment group, after 3 days of last administration of the powder, blood and liver tissues are collected, and blood metabolism indexes and indexes related to liver fat metabolism are detected.
The results of the prevention and treatment groups were statistically as follows:
in the prevention experiment, the experimental data (mean + -SEM) of the control group filled with drinking water and the treatment group filled with the powder of the invention are as follows:
note: data shoulder marks between groups indicate significant differences (P<0.05)。
In a treatment experiment, the fatty liver dairy cows are respectively drenched with drinking water and the powder of the invention, and experimental data (mean + -SEM) are as follows:
note: data shoulder marks between groups indicate significant differences (P<0.05)。
To sum up: (1) the experimental result adopts SPSS19.0 software to carry out data processing, and the indexes of non-esterified fatty acid, beta-hydroxybutyric acid, glutamic-oxalacetic transaminase and glutamic-pyruvic transaminase in the blood of the milk cow are obvious after the powder is irrigated in both prevention and treatment experimental groups (the indexes are all shown in the specification)P< 0.05) reduction in blood glucose levels and (glucose content in blood is significant: (PLess than 0.05) rises.
(2) In prevention and treatment experiments, after the powder is drenched, the wet weights of total cholesterol and triglyceride in blood and triglyceride in liver are all obvious (P< 0.05) lowering.
(3) In a prevention experiment, the incidence of the fatty liver of the postpartum dairy cow is obviously reduced; in treatment experiments, fatty liver cows have a significantly reduced accumulation of liver lipids. Therefore, the experiment completely proves that the invention has the effect of effectively preventing and treating the fatty liver of the dairy cow in the perinatal period.
The invention mainly highlights that the powder can prevent and treat fatty liver of the dairy cow in the perinatal period. In addition, the linarin, as a flavonoid substance, can relieve the toxic effect of high-concentration NEFA on liver cells through the direct protection effect on a biological membrane, thereby playing the role of protecting the liver. In addition, the soybean phospholipid is added into the powder, so that the solubility and bioavailability of the linarin are obviously improved, the linarin can be better absorbed by an organism, and the functions of protecting the liver and promoting the decomposition of liver fat are exerted. In addition, the matching use of the rumen bypass choline and the selenium can play a role in double protection of the liver and promote the discharge of triglyceride in the liver, and the addition of the calcium bicarbonate is beneficial to improving the blood calcium level and reducing the incidence rate of hypocalcemia. In a word, the invention can effectively maintain the blood sugar and blood calcium level of the dairy cow in the perinatal period while preventing and treating the liver fat accumulation of the dairy cow in the perinatal period and reducing the fatty liver morbidity, thereby reducing the treatment cost in the dairy cow breeding process and improving the economic benefit of the dairy cow breeding industry.
Rumen-bypass glucose and mineral elements are added into the powder, so that energy supply of postpartum cows can be quickly recovered, and energy negative balance caused by insufficient intake of dry matters of the cows in perinatal period can be effectively improved.
Claims (1)
1. A powder preparation taking linarin as a main component for preventing and treating fatty liver of perinatal dairy cows is characterized in that: the weight portions of the effective components are as follows: 29-33 parts of rumen bypass glucose, 15-20 parts of calcium bicarbonate, 10-15 parts of rumen bypass choline, 6-10 parts of iodized salt, 10-14 parts of baking soda, 6-11 parts of sodium selenite, 4-8 parts of soybean phospholipid and 2-4 parts of linarin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011285132.5A CN112472719A (en) | 2020-11-17 | 2020-11-17 | A powder containing linarin as main ingredient for preventing and treating fatty liver of perinatal milk cow |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011285132.5A CN112472719A (en) | 2020-11-17 | 2020-11-17 | A powder containing linarin as main ingredient for preventing and treating fatty liver of perinatal milk cow |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112472719A true CN112472719A (en) | 2021-03-12 |
Family
ID=74930926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011285132.5A Pending CN112472719A (en) | 2020-11-17 | 2020-11-17 | A powder containing linarin as main ingredient for preventing and treating fatty liver of perinatal milk cow |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112472719A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112655826A (en) * | 2020-11-27 | 2021-04-16 | 吉林大学 | Rumen-bypass health-care granules for preventing and treating fatty liver of dairy cow in perinatal period |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106806374A (en) * | 2016-12-23 | 2017-06-09 | 刘春海 | A kind of composition for preventing and treating perinatal period ruminant ketoacidosis and fatty liver |
| CN107279510A (en) * | 2017-06-02 | 2017-10-24 | 上海光明荷斯坦牧业有限公司 | A kind of premix for preventing and treating Diseases of Cow fatty liver and its related application |
| CN108030808A (en) * | 2017-12-28 | 2018-05-15 | 吉林大学 | A kind of pulvis using lotus leaf as the prevention Diseases of Cow syndrome of main component |
| CN109771467A (en) * | 2019-01-17 | 2019-05-21 | 吉林大学 | A kind of compound eucommia bark concentrate improving Diseases of Cow resistance |
-
2020
- 2020-11-17 CN CN202011285132.5A patent/CN112472719A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106806374A (en) * | 2016-12-23 | 2017-06-09 | 刘春海 | A kind of composition for preventing and treating perinatal period ruminant ketoacidosis and fatty liver |
| CN107279510A (en) * | 2017-06-02 | 2017-10-24 | 上海光明荷斯坦牧业有限公司 | A kind of premix for preventing and treating Diseases of Cow fatty liver and its related application |
| CN108030808A (en) * | 2017-12-28 | 2018-05-15 | 吉林大学 | A kind of pulvis using lotus leaf as the prevention Diseases of Cow syndrome of main component |
| CN109771467A (en) * | 2019-01-17 | 2019-05-21 | 吉林大学 | A kind of compound eucommia bark concentrate improving Diseases of Cow resistance |
Non-Patent Citations (2)
| Title |
|---|
| ZHUANG ZHEN-JIE等: "Linarin Enriched Extract Attenuates Liver Injury and Inflammation Induced by High-Fat High-Cholsterol Diet in Rat", 《EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE》 * |
| 付金芳等: "蒙花苷磷脂复合物的制备及其药动学评价", 《中国现代应用药学》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112655826A (en) * | 2020-11-27 | 2021-04-16 | 吉林大学 | Rumen-bypass health-care granules for preventing and treating fatty liver of dairy cow in perinatal period |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0709083A2 (en) | porphyra compositions and methods of preparing and using these | |
| CN111494353A (en) | Pharmaceutical and nutraceutical compositions of abscisic acid | |
| CN104304679B (en) | A kind of B B-complex C, E immune polysaccharide microemulsion preparation and its preparation method and application | |
| JP5484340B2 (en) | Ruminant bloating treatment | |
| NO328761B1 (en) | Method of delivering bioavailable methionine for non-therapeutic treatment to a cow | |
| CN112472719A (en) | A powder containing linarin as main ingredient for preventing and treating fatty liver of perinatal milk cow | |
| CN103006709B (en) | Bee-pollen buccal tablet for preventing and treating alcoholic fatty liver | |
| EP3193629B1 (en) | Anti-diarrhea formulation which avoids antimicrobial resistance | |
| CN101982176B (en) | Compound sodium selenite-vitamin E oral nano-emulsion preparation for livestock and preparation method thereof | |
| JP2021508433A (en) | Carob fruit composition and its preparation method and application | |
| WO2009139468A1 (en) | Coccidiosis control agent and feed containing the same | |
| JPH0713022B2 (en) | Veterinary medicine | |
| JP4428553B2 (en) | Prophylactic and / or therapeutic agent for domestic animals | |
| CN111494359A (en) | Dihydromyricetin with alcohol effect dispelling function | |
| CN104739964B (en) | A kind of snail sobering preparation and preparation method thereof | |
| CN114468150B (en) | Application of gentisic acid in promoting growth and rumen development of young ruminants | |
| KR101870280B1 (en) | A composition for removing hangover comprising an extract of Cinnamomum cassia Presl and cinnamomi petiole | |
| CN105558435A (en) | Feed additive for preventing and treating silver carp hemorrhagic disease | |
| Tufani et al. | Rumen acidosis in small ruminants and its therapeutic management | |
| CN101904856A (en) | Application of 1,6-diphosphofructose and derivative thereof in preparing animal medical health care products | |
| RU2338546C2 (en) | Method of obtaining of preparation for prevention or treatment of radiative lesions of organism | |
| CN112841431A (en) | Compound formula for preventing and treating dairy cow ketosis suitable for oral administration | |
| CN110038090A (en) | A kind of compound celery oil self-emulsifying soft capsule and preparation method thereof with antigout effect | |
| CN104146271A (en) | Metabolism regulating and liver protecting nutritional supplement, preparation method and applications thereof | |
| JP2009057336A (en) | Wound-healing promoting composition comprising extract of momordica grosvenori and its application method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210312 |
|
| RJ01 | Rejection of invention patent application after publication |